The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer

• DOI: 10.18632/oncotarget.19513
• Publication Date: 2017-07-24T18:12:06Z
• Authors: Luo Lu; Yaoyu Chen; Yu Zhu
• Keywords: Phosphofructokinase 2

// Luo Lu 1 , Yaoyu Chen and Yu Zhu Department of Hematology, The First Affiliated Hospital Nanjing Medical University, Jiangsu Province Hospital, 210029, China Correspondence to: Zhu, email: [e-mail] Keywords: PFKFB3, glycolysis, autophagy, solid tumors, hematologic malignancies Received: April 23, 2017 Accepted: July 12, Published: 24, ABSTRACT 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatases (PFKFBs) are bifunctional enzymes which regulate the transformation between fructose-2, 6-bisphosphate (F2, 6BP) fructose-6-phosphate (F6P) in process glucose metabolism. Among four isozymes (PFKFB1-4), PFKFB3 has stronger kinase activity than phosphatase activity, resulting synthesis F2, 6BP promotion glycolysis. Additionally, plays a key role cell cycle regulation. It been confirmed that is upregulated variety tumor cells, inhibition it results suppression growth cells by downregulating glycolytic flux. expected to release drug resistance prevent disease progression inhibition. Recent studies have also shown efficacy not only related but autophagy. Here, we reviewed biological characteristics regulation pathway metabolism manipulated other regulatory mechanisms non-hematologic malignant cells.